secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2026-06-08T11:05:51+00:00
Accession:  0000879169-26-000040
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte to acquire Vega Therapeutics for $1.25B upfront; total up to $2.0B
-------------------------------------------------------------------------

- Acquires Vega Therapeutics from Star Therapeutics; adds VGA039, a Phase 3 anti-Protein S mAb for von Willebrand disease.
- Star receives $1.25B upfront; up to $750M in sales milestones for total consideration of $2.0B.
- VGA039 has Breakthrough Therapy, Fast Track, and orphan drug designations from FDA; Phase 3 VIVID-6 trial ongoing.
- Transaction approved by both boards; expected to close in Q3 2026 subject to HSR review.
- Incyte expects a ~$1.25B R&D charge in Q3 and full year 2026 GAAP and non-GAAP results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000040/0000879169-26-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000040/incy-20260608.htm
  HTML page:      https://secwatch.observer/filing/0000879169-26-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer